Zevalin to Be Reviewed by FDA on September 11, 2001

[Guest guest]

IDEC Pharmaceuticals announced that ZEVALIN, an

investigational agent for the treatment of relapsed or

refractory, low grade, follicular, CD20-positive

transformed, B-cell non-Hodgkin's lymphoma (NHL) and

Rituximab-refractory follicular NHL, will be reviewed

by the Oncologic Drugs Advisory Committee (ODAC) of

the FDA on September 11, 2001.

As a Class II response under FDA guidelines, the FDA

may approve, not approve, or raise additional

questions regarding the BLA at any time within six

months from the resubmission date.

IDEC Pharmaceuticals focuses on the commercialization

and development of targeted therapies for the

treatment of cancer and autoimmune diseases. IDEC's

antibody products act chiefly through immune system

mechanisms, exerting their effect by binding to

specific, readily targeted immune cells in the

patient's blood or lymphatic system. For a menu of

IDEC's current news releases and quarterly reports or

to retrieve a specific release, call (888) 329-2309.

On the Internet, check the News Center at IDEC's

website: http://www.idecpharm.com.

The company's headquarters are located at 3030 Callan

Road, San Diego, CA 92121.

__________________________________________________